Member Info for Muck165

In that vein, and to give a flavour, BBI were sold in 2021 for £400m.

Should be remembered that they provide antibodies, antigens, labels, and complementary reagents, as well as do everything ABDX does. But still…..

https://www.prnewswire.com/news-releases/novo-holdings-acquires-bbi-group-301312183.html#:~:text=COPENHAGEN%2C%20Denmark%2C%20June%2015%2C,value%20of%20over%20GBP%20400

Well said, and in fewer words than I normally manage! Maybe I should try the wine.

Longer term, well more medium term I think, I expect that Chris Hand will be looking for a capital exit. He’s already built, AIM listed and then sold one drugs of abuse LFT diagnostics company (Cozart, now part of Abbot) for £65m, and he must be looking at ABDX as his juicy retirement fund. He’s 63 next month.

For awareness btw, there is a company called AbcDx that are trying to do exactly what Upfront are. They are being assisted by BBI (one of our major competitors), but seem to me to be AT LEAST 6 months behind Upfront.

https://www.abcdx.ch/solution/lvocheck

https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2023.1327348/full

TBH I think one advantage here is that unlike many other stocks, we’re not waiting on a single catalyst but instead have our fingers in so many pies. At the moment I’m watching out for any news on;

Septiloop sales/take up.

Salistick launch in new territories and possibly FDA authorisation. Equally any new U.K. retailers

Upfront funding and UKCA

Another own label Boots product(s)

News on EcoFlo pro type testing/results and possible commercial launch

And this is all just what’s on my radar for Q2/3, and ignores 52North, FOFH, and any other surprises we know nothing about.

I never put too much store in analyst predictions but 78p really doesn’t sound ridiculous to me as a 12 month target. If we were to do it though, the beauty is that it should be founded on solid year on year annuity income.

And as I’ve said before, our risk is spread widely across customers who have all spent years getting to where they are, and who therefore have every incentive to achieve commercial success.

Don't think so Ant - Everything at 10.34 is definitely a buy, and I suspect so are those at 10.12.

Only the trades at 10 dead are sells I think.

Another observation, this time just a post from Upfront.

https://www.linkedin.com/posts/upfrontdiagnostics_timeislife-activity-7188440790136676352-hZJU?utm_source=share&utm_medium=member_desktop

Upfront have been working with North East NHS Hospitals since 2018 and, as you can see from the post, that means they have built a product that not only works, but has been made specifically for use in the NHS. Its little wonder they were selected for the IDAP scheme and their LVOne test is, for my money, destined for widespread NHS adoption. The next I think we will hear from Upfront, which I suspect will come pretty shortly, is a successful latest funding round. Then it will be UKCA this quarter and then very quick NHS adoption and ergo manufacturing requirements.

Worth noting again that Upfront have been telling people that they can manufacture at scale. Well, we are their only manufacturing partner as far as I can tell.

Another observation…

It would appear that Salignostics have become a client of Sheng Enterprises, a Chinese company helping Israeli companies get a foothold in the Chinese market. More detail can be found here under the March 24 event “ The Israel Medical Device Special Matchmaking Event” - https://www.sheng-cn.com.cn/events-meetings/.

More on Sheng generally here - https://www.sheng-cn.com.cn/

More for awareness really

Just another little observation….

ABDX latest blog was about security of supply chain, written by our COO Mark Jones - https://www.abingdonhealth.com/ensuring-your-critical-components-are-protected-the-importance-of-supply-agreements/

Whist this is undated, it appears to me to be a new news release from a company called Rosti, who have partnered with is for injection moulding.

https://rosti.com/rosti-uk-secures-exciting-new-project-with-abingdon-health/

Just interesting that focus lately has been on supply and security of manufacturing components.

This is worth a listen to - yes, its about the Helix IPO but it all adds to knowledge!

Of particular interest to me was at about 59 seconds in, when the interviewer commented how the Helix IPO raise suddenly went from Lukewarm to hot, with an original intent to raise £3-4m but ending up with about £20m of demand.

Georgina are looking to raise £3m, using the same broker as Helix.

https://www.youtube.com/watch?v=2uIlWZKSvYY

Even the comparables Carroll mentioned in the interview (£13m Helix, £13m GE on IPO) make our £2m MCAP look ridiculous, particularly give our revenue underpin.

Positives for me are

1) Can’t see him doing that interview if he had concerns about EP145

2) He didn’t express any concern about the deal completing

3) he again confirmed works were progressing pending approval

Not the most forthcoming or energetic person in interview, but a solid experienced guy.

I see that under the “Reports” section of its website, Georgina are including MMM RNS announcements. Just wondering, but is this a new development, or have they been doing it for a while? Just seems a little odd to be doing this unless confidence deal completion is high.

https://www.georginaenergy.com/about/reports/

They also say “ Georgina Energy is seeking to raise GBP 3 Million to complete a Reverse take over on the London Stock Exhange/LSE with re admission in Q2 2024, subject to shareholder and regulatory approvals.”

https://www.georginaenergy.com/about/georginas-journey/

Apologies for any ignorance or repetition of what’s known! I just don’t follow this one as closely as others.

Hi Wyn

Agree - getting regulatory approval is like wading through treacle and all sorts of extra requests can delay things. But the point still remains valid - it’s reasonable to think we’re entering a time window when a decision might be made.

And the Times of Israel quoted Krieff last month as saying Salistick is currently being “positioned” in the States.

How approval might directly affect ABDX I don’t know - we’re unlikely to be a US distributor (although that would be amazing!), but we will still be manufacturing.

Just another small observation…

We know that Salignostics got UKCA approval in March 23, and that they also have CE. We also know they had initial meetings with the FDA by at least November 21.

Now, I’m not entirely sure what FDA approval pathway they’d have to follow, and so what additional requirements the FDA might have over and above conformity assessments in the U.K/EU

What I do know is that for a De Novo application, being the pathway for a device with no existing substantial equivalent, the FDA aim to give a decision within 150 days of having all necessary information.

So if we got UKCA in March 23, I think it’s reasonable to think an FDA decision can’t be too far away (assuming there’s been no hiccups!)

1. Boots have little pop up that tells you how many times an item has been viewed, and how many times its been added to basket in the last 24 hours. I've been watching this daily (sad I know) since our Vit D and Iron tests launched, and we are consistently ahead of the MHC equivalents, despite no price differential. Boots are selling between 25 and 50 of each product each day, online only.

Loop - - their CEO has been heavily publicising a speaking session he is delivering at the EIT Health Summit on 18-19 April. Perhaps we might get a UKCA announcement before then?

As I say, just little observations...

More good news from the Upfront CEO today

https://www.linkedin.com/posts/gonzaloladreda_timeislife-activity-7183373180240019457-NJE-?utm_source=share&utm_medium=member_desktop

Don’t know what happened there! Just look at the recommendation letter on page 20, which has come from one of the largest medical device manufacturers in the world.

I lied! Last one, promise!

On page 20 of the presentation Upfront show a letter of recommendation from Medtronic, which says “The current stroke penetration rate of of

Final one from me, but I came across this pitch update because a company called Odelle posted this on LinkedIn (which Yates liked)

https://www.linkedin.com/posts/odelle-technology_excellence-diagnostics-activity-7183021230294192129-2eH9?utm_source=share&utm_medium=member_desktop

So it’s interesting to see what Odelle do, and the companies they’ve worked with

https://odelletechnology.com/about-us/

Overall it’s really obvious that Upfront have a very well planned and professional roadmap to market, involving professional and experienced consultants and with support of regulatory health powers that be. Great customer for us.

Also worth noting again that one of the benefits of IDAP is the potential for “Exceptional Use Authorisation” from the MRHA, which could come sooner than anyone expects.

https://www.gov.uk/government/publications/the-innovative-devices-access-pathway-idap/the-innovative-devices-access-pathway-idap-pilot-phase